Novo Nordisk A/S · NVO · FY2026 Q3 · Calendar Q4 2026
Novo Nordisk Q3: obesity demand supports growth, pricing and LOE remain risks
Q3 analysis points to ongoing GLP-1 volume growth—especially Wegovy pill uptake—as a near-term growth support, while price erosion, loss of exclusivity and payer pressure temper confidence in durability.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about NVO FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The supplied Q3 analysis describes stronger operating profit and continued obesity-product momentum, alongside expanded product and geographic plans. It also identifies ongoing pricing and loss-of-exclusivity pressure and a CFO transition. The supplied materials do not include verified actual-versus-consensus results.
Guidance delta
The Q3 analysis says 2026 sales and profit growth guidance was raised to -2% to +2% at constant exchange rates. The prior-quarter analysis lists full-year sales growth guidance of 0% to 6%; these summaries do not reconcile the apparent direction of change, so the delta is unclear.
Key takeaways
- Wegovy pill uptake and continued GLP-1 volume expansion are identified as principal growth drivers.
- The analysis highlights international rollout plans and prospective launches including CagriSema and Frehemgo, subject to regulatory approval.
- Management's outlook is framed against pricing pressure and loss-of-exclusivity exposure in key markets.
- The supplied analysis reports a CFO transition, with Luigi La Corte to assume the role in 2027.
Management priorities
- Expand the Wegovy pill into additional markets.
- Advance CagriSema, Frehemgo and other pipeline programs, subject to regulatory outcomes.
- Pursue international market penetration and growth in obesity treatments.
Follow NVO with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationNovo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RPRX Royalty Pharma plc | FY2026 Q3 · Calendar Q4 2026 | — | +1.4% | Royalty Pharma Raises Guidance as Receipts and Co-Funding Expand |
| ZBH Zimmer Biomet Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +14.6% | Zimmer Biomet raises 2026 outlook as hip and technology growth offset knee weakness |
| MDLN Medline Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +16.2% | Medline Raises 2026 Organic Sales Outlook on 10% Q3 Growth |
| CRL Charles River Laboratories International, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -6.0% | Charles River raises FY2026 outlook after strong Q3; demand and margins improve |
| UTHR United Therapeutics Corporation | FY2026 Q3 · Calendar Q4 2026 | — | +0.6% | United Therapeutics’ record quarter highlights Tyvaso growth and pipeline execution |
| AMGN Amgen Inc. | FY2026 Q3 · Calendar Q4 2026 | +11.4% | +1.6% | Amgen Q3: Growth Drivers, Pipeline Progress and Higher 2026 Guidance |
Latest beats and misses
Who reports nextBeat on EPS
- WTRGFY2026 Q3 · November 3, 2026+13.7% EPS+2.5% move
- LTMFY2026 Q3 · November 3, 2026+25.2% EPS+9.5% move
- AIZFY2026 Q3 · November 3, 2026+29.5% EPS+4.2% move
- AIZNFY2026 Q3 · November 3, 2026+36.0% EPS+0.5% move
- SMCIFY2027 Q1 · November 3, 2026+47.2% EPS-4.2% move
- XYZFY2026 Q3 · November 3, 2026+9.7% EPS+14.9% move
Missed on EPS
- BSACFY2026 Q3 · October 30, 2026-20.0% EPS-3.0% move
- TXFY2026 Q3 · November 3, 2026-24.9% EPS-0.0% move
- CHTFY2026 Q3 · November 4, 2026-55.7% EPS+0.9% move
- TOSTFY2026 Q3 · November 3, 2026-20.1% EPS+5.9% move
- CPNGFY2026 Q3 · November 3, 2026-90.3% EPS+13.3% move
- TLNFY2026 Q3 · November 3, 2026-65.4% EPS+7.3% move
Get the NVO recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-04T18:14:44.133116+00:00
- FN2 earnings calendar · 2026-11-04T01:23:13.345574+00:00
- Polygon adjusted daily market bars · 2026-11-04T19:10:45.175980+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-04T19:10:45.173663+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-04. For educational purposes only; not investment advice.